Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000362106

Medchemexpress LLC Resomelagon acetate (AP1189 acetate) | 1809420-72-1 | 99.8% | 358.35 | 50 MG
SDP

Catalog No. 5000362106
Encompass_Preferred

Resomelagon (AP1189) acetate is a potent, orally active melanocortin receptor (MR) agonist targeting MC1 and MC3. It induces ERK1/2 phosphorylation and Ca2+ mobilization, and exhibits anti-inflammatory activity. Resomelagon acetate can be used for obesity and chronic inflammation research.

  • Potent, orally active melanocortin receptor agonist
  • Targets MC1 and MC3
  • Induces ERK1/2 phosphorylation and Ca2+ mobilization
  • Exhibits anti-inflammatory activity
  • Inhibits TNF-α release and efferocytosis
  • Promotes resolution of acute inflammation in vivo
  • Reduces arthritis in mice

Catalog No. 50-003-62106 Supplier Medchemexpress LLC Supplier No. HY147301A50MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Resomelagon (AP1189) acetate is a potent, orally active melanocortin receptor (MR) agonist targeting MC1 and MC3. It induces ERK1/2 phosphorylation and Ca2+ mobilization, and exhibits anti-inflammatory activity. Resomelagon acetate can be used for obesity and chronic inflammation research.

  • Potent, orally active melanocortin receptor agonist
  • Targets MC1 and MC3
  • Induces ERK1/2 phosphorylation and Ca2+ mobilization
  • Exhibits anti-inflammatory activity
  • Inhibits TNF-α release and efferocytosis
  • Promotes resolution of acute inflammation in vivo
  • Reduces arthritis in mice

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.